Program
Simvastatin
Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.
Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.
Drug pageSimvastatin: every studyMany companies study it; this page follows only the 65 they lead. All 370 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 290 open or running | phase 4since Sep 7, 2005 | Sep 21, 2004 | none ahead |
| Abbott | 80 open or running | phase 3since Mar 25, 2004 | Mar 25, 2004 | none ahead |
| Eli Lillyits history only | 60 open or running | phase 2since Apr 15, 2010 | Apr 15, 2010 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Merckits history only | 60 open or running | phase 3since May 24, 2007 | May 24, 2007 | none ahead |
| Pfizerits history only | 40 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 21, 2010 | Jul 21, 2010 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Entero Therapeuticsits history only | 10 open or running | early phase 1since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
Also a collaborator on its studies: Immunogenics, Regeneron Pharmaceuticals, Celerion and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Abbott only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2004First study: phase 3 study in HypercholesterolemiaFirst studyNCT00080275 · 600 enrolled
- May 3, 2004Phase 3 study in HypercholesterolemiaNCT00082251
- Jul 6, 20062 phase 3 studiesNCT00349375, NCT00352183
- Aug 8, 20062 phase 3 studies in HyperlipidemiasNCT00362206, NCT00362934
- Apr 23, 2007Phase 3 study in HyperlipidemiasNCT00465088 · 199 enrolled · United States
- Jun 26, 2012Phase 3 study in DyslipidemiasNCT01674712 · 575 enrolled · Argentina, Czech Republic, Germany and more
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
All 8 Abbott leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01674712Dyslipidemias · Argentina, Czech Republic, Germany and more | 3 | Completed | Oct 2013 | 575 |
| NCT00465088Hyperlipidemias · United States | 3 | Completed | Feb 2008 | 199 |
| NCT00362934Hyperlipidemias · Bulgaria, Czech Republic, Germany and more | 3 | Completed | Aug 2008 | 516 |
| NCT00362206Hyperlipidemias · Greece, Israel, Romania and more | 3 | Completed | Sep 2008 | 423 |
| NCT00352183Cardiovascular Diseases · Australia, Estonia, Hungary and more | 3 | Completed | Aug 2008 | 450 |
| NCT00349375Hyperlipidemias · Czech Republic, Denmark, France and more | 3 | Completed | Sep 2008 | 1,040 |
| NCT00082251Hypercholesterolemia | 3 | Completed | ||
| NCT00080275Hypercholesterolemia | 3 | Completed | 600 |
How it is read
Names in the registry
- “Simvastatin”, 44 entries
- “simvastatin”, 14 entries
- “ezetimibe (+) simvastatin”, 9 entries
- “Fenofibrate/Simvastatin”, 5 entries
- “Ezetimibe + Simvastatin”, 4 entries
Codes read as this program: MK0733.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 35 studies
- Diabetes Mellitus, Type 2, 9 studies
- Hyperlipidemias, 7 studies
- Cardiovascular Diseases, 3 studies
- Hypertension, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.